You make compelling points about the advantages of a $20-30 million cash deal, particularly in terms of funding essential research and buying time for German GBA funding.
All these initiatives could fundamentally shape OncoSil's future in a positive way.
However, I would argue against giving up U.S. rights in return for immediate cash and royalties.
The U.S. market represents a significant opportunity, especially if FDA approval is secured. It would be a long-term play that could pay off exponentially, far outweighing the short-term gains of a quick cash influx.
Holding onto U.S. rights could prove to be vital for the company's long-term valuation and success.
- Forums
- ASX - By Stock
- OSL
- Pancreatic Cancer in the Media
Pancreatic Cancer in the Media, page-61
-
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $45.40M |
Open | High | Low | Value | Volume |
1.1¢ | 1.2¢ | 1.1¢ | $11.23K | 958.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 4663993 | 1.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 2185591 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 4463993 | 0.011 |
30 | 16097280 | 0.010 |
13 | 7861222 | 0.009 |
8 | 5387500 | 0.008 |
6 | 2714285 | 0.007 |
Price($) | Vol. | No. |
---|---|---|
0.012 | 1977665 | 4 |
0.013 | 11622498 | 7 |
0.014 | 5914139 | 8 |
0.015 | 8743600 | 5 |
0.016 | 3766668 | 2 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |